VanEck Pharmaceutical ETF
PPH
53 hedge funds and large institutions have $48.9M invested in VanEck Pharmaceutical ETF in 2014 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 16 increasing their positions, 13 reducing their positions, and 3 closing their positions.
167% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 3
23% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 13
20% more capital invested
Capital invested by funds: $40.9M → $48.9M (+$8M)
10% more funds holding
Funds holding: 48 → 53 (+5)
0.28% more ownership
Funds ownership: 15.27% → 15.55% (+0.28%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
+$4.54M |
| 2 |
HighTower Advisors
Chicago,
Illinois
|
+$2.01M |
| 3 |
B
Baird
Milwaukee,
Wisconsin
|
+$1.31M |
| 4 |
BCM
Barometer Capital Management
Toronto,
Ontario, Canada
|
+$599K |
| 5 |
U
UBS
Zurich,
Switzerland
|
+$574K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
-$5.68M |
| 2 |
Goldman Sachs
New York
|
-$657K |
| 3 |
MIM
Macroview Investment Management
Bethesda,
Maryland
|
-$388K |
| 4 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$201K |
| 5 |
CCT
Country Club Trust
Kansas City,
Missouri
|
-$201K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
WEC
51
Winslow Evans & Crocker
Boston,
Massachusetts
| $5.84K | +$5.66K | +100 | New |
|
|
FNBT
52
FineMark National Bank & Trust
Fort Myers,
Florida
| $3K | – | – | – |
|
53
Walleye Trading
New York
| $18 | +$17K | +300 | New |
|
|
54
JP Morgan Chase
New York
| – | -$5.68M | -106,981 | Closed |
|
|
CCT
55
Country Club Trust
Kansas City,
Missouri
| – | -$201K | -3,783 | Closed |
|
|
ASN
56
Advisory Services Network
Atlanta,
Georgia
| – | -$40K | -750 | Closed |
|
PPH Hedge Fund Activity: Q1 2014 in Review
53 of the 3,464 institutional investors tracked by Wall St. Rank reported a position in VanEck Pharmaceutical ETF (PPH) for Q1 2014, worth a combined $48.9M — up 20% from $40.9M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new PPH positions and 3 closed out — a net gain of 5 holders — while 16 added to existing stakes and 13 trimmed.
The largest buyer was Raymond James & Associates, opening a new position worth an estimated $4.54M. The largest seller was JP Morgan Chase, exiting entirely with an estimated $5.68M sold.
- 53 institutional investors held VanEck Pharmaceutical ETF (PPH) as of Q1 2014, up from 48 in Q4 2013.
- Funds reported $48.9M of VanEck Pharmaceutical ETF stock for Q1 2014, up 20% quarter-over-quarter.
- 8 funds opened new VanEck Pharmaceutical ETF positions in Q1 2014 and 3 closed out, a net change of +5 holders.
- The largest VanEck Pharmaceutical ETF buyer in Q1 2014 was Raymond James & Associates, an estimated $4.54M added.
- The largest VanEck Pharmaceutical ETF seller in Q1 2014 was JP Morgan Chase, an estimated $5.68M sold.
Based on aggregated 13F filings for Q1 2014.